Skip to main content
OpenTrials
Completed

NCT Number: NCT00668447

Soy and Isoflavones Effect on Bone

The purpose of this study is to test the effect of 1 year of added dietary soy protein and/or soy isoflavones on bone mineral density in late postmenopausal women.

Completed

Looking for future studies?

Notify Me

Key information

Age range

65 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

University of Connecticut Health Center

Farmington, Connecticut, 06030, United States

About this study

Although soy foods contain several components (isoflavones and amino acids) that could potentially have positive effects on bone health, there are few long term, large, clinical trials using soy as a means of improving bone mineral density. The objective of this study is to provide daily soy protein and isoflavones to healthy older women in order to answer three major questions:

  • Does soy protein alone affect bone metabolism?
  • Do isoflavones, given with soy protein, affect bone metabolism?
  • What dose of isoflavones affects bone in older women?

We hypothesize that soy protein will have a beneficial effect on bone in older women compared to control protein. Further, we hypothesize that there will be an additional benefit to bone in women who receive soy protein plus isoflavones (at both doses) compared to soy protein alone.

Both control and soy proteins used in the study were isolates, meaning they were the highest concentration of protein (85-90% by weight) in order to minimize the volume of protein supplement that each woman was asked to ingest on a daily basis. The soy protein was an alcohol-washed, soy protein isolate containing 90% protein and negligible isoflavone (0.2 mg/g product). The control protein was a mix consisting of 50% protein from sodium caseinate, 25% protein from whey protein and 25% from egg white protein. The use of a mix of proteins as a control provides a more balanced level of amino acids, mimics the real life mix of proteins that humans typically consume, and avoids the unique characteristics of one source of protein. In order to maintain the dietary protein intake constant, the participant was counseled to decrease her intake of other sources of protein from primarily animal sources by approximately 3 ounces per day (the approximate equivalent of the protein powders). The isoflavones tablets each contained 57 mg of total isoflavone from primarily genistein, glycitein, and daidzein and their beta-glycosides.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Postmenopausal women 65 years old or older
  • Able to travel to the clinical sites for follow-up visits

Exclusion criteria

  • History of disease that may affect bone metabolism (including Paget's disease, primary hyperparathyroidism, osteomalacia, untreated hyperthyroidism, or multiple myeloma)
  • Cancer of any kind (except basal or squamous cell of skin) in past 5 years
  • Use of any of the following medications within the past 2 years: calcitonin, calcitriol, heparin, phenytoin, phenobarbital
  • Use at any time of bisphosphonates, long-term corticosteroids (over 6 months), methotrexate, or fluoride
  • Estimated creatinine clearance less than 50 ml/min
  • History of chronic liver disease or evidence of liver disease on screening
  • History of hip fracture
  • Known vertebral fracture within the past year
  • Vegans

Treatment and study plan

Soy Isolate

Dietary Supplement

20 grams of powder mixed in beverages or food daily for one year

Other names: Pro Fam 930, 066-930

Control protein

Dietary Supplement

20 grams of powder mixed in beverages or food daily for one year

Novasoy isoflavones

Dietary Supplement

3 tablets daily for one year

Placebo tablets

Dietary Supplement

3 tablets daily for one year

Primary outcomes

  1. Bone turnover markers

    Time frame: baseline, 3 months, and 1 year

Secondary outcomes

  1. Bone Mineral Density

    Time frame: Baseline, 6 and 12 months

  2. Quality of life measured by Medical Outcomes Short Form

    Time frame: Baseline, 6 and 12 months

  3. Medication Side Effects

    Time frame: 3 , 6, 9, and 12 months

  4. Adherence to dietary intervention through the use of 24-hour recall

    Time frame: 3, 6, 9, and 12 months

  5. Long-term medication behavior self-efficacy scale

    Time frame: 3, 6, 9, and 12 months

Sponsors and collaborators

Lead sponsor

United States Department of Agriculture (USDA)

Fed

Collaborators

  • University of Connecticut

Registry information

Official study title

Soy Proteins and Isoflavones Impact Bone Mineral Density in Older Women

Important dates

Study start
2001
Primary completion
2005
Study completion
2005
First posted
Apr 29, 2008
Registry last updated
Apr 29, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.